BCDA BioCardia

BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

SAN CARLOS, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies today announced that Peter Altman, Ph.D., Biocardia’s Chief Executive Officer will give a virtual corporate presentation at the LD Micro 500 taking place online on Tuesday, September 1, 2020 at 10:20 AM ET followed by a live question and answer session with registered investors and other conference attendees.

Webcast link:

In addition, Dr. Altman will be available for virtual one-on-one meetings beginning on September 1, 2020 and through September 4, 2020.  To schedule a meeting, please contact Eric Lahiji at .

About BioCardia

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit .

Media Contact:

Michelle McAdam, Chronic Communications, Inc.



(310) 902-1274

Investor Contact:

David McClung, Chief Financial Officer



(650) 226-0120

EN
26/08/2020

Underlying

BCDABioCardia

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCardia

 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Forma...

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary clinical consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) on our CardiAMP Cell Therapy intended for treatment of Heart Failure with Reduced Ejection Fraction (HFrEF). The meeting was held in further preparation fo...

December 16, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Announces Election of New Board Director, Marvin Slosman and...

BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno SUNNYVALE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the election of Mr. Marvin Slosman to its Board of Directors, effective December 2, 2025. Dr. Richard Krasno, who has served on the Board since 2016, has completed his term and departed the Board effective December 2, 2025. “We are very please...

December 3, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failu...

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will participate at the CSI Focus Devices in Heart Failure this week in Frankfurt, Germany. BioCardia’s President and Chief Executive Officer, Peter Altman, PhD, will make an invited presentation entitled, “Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejection.” Meetin...

December 1, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Strengthens Leadership Team with The Addition of Farhan Shah...

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served a...

November 24, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Reports Third Quarter 2025 Business Highlights and Financial...

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2025 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following mana...

November 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch